Advertisement
Advertisement

CYTK

CYTK logo

Cytokinetics Inc.

65.42
USD
Sponsored
+0.05
+0.08%
Apr 16, 16:00 UTC -4
Closed
exchange

After-Market

64.75

-0.67
-1.02%

CYTK Earnings Reports

Positive Surprise Ratio

CYTK beat 14 of 40 last estimates.

35%

Next Report

Date of Next Report
Apr 30, 2026
Estimate for Q1 26 (Revenue/ EPS)
$8.79M
/
-$1.68
Implied change from Q4 25 (Revenue/ EPS)
-50.51%
/
+12.00%
Implied change from Q1 25 (Revenue/ EPS)
+456.49%
/
+20.86%

Cytokinetics Inc. earnings per share and revenue

On Feb 24, 2026, CYTK reported earnings of -1.50 USD per share (EPS) for Q4 25, missing the estimate of -1.48 USD, resulting in a -0.97% surprise. Revenue reached 17.75 million, compared to an expected 7.05 million, with a 151.86% difference. The market reacted with a -10.29% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 10 analysts forecast an EPS of -1.68 USD, with revenue projected to reach 8.79 million USD, implying an increase of 12.00% EPS, and decrease of -50.51% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Apr 08, 2026 For Q1 26
Estimate
-$0.76
Actual
-$0.79
Surprise
-2.68%
logo
NovaBridge Biosciences - ADR
Report Date
Apr 07, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.28
Surprise
-421.58%
logo
Scilex Holding Company Common Stock
Report Date
Apr 10, 2026 For Q4 25
Estimate
-$0.47
Actual
-$2.21
Surprise
-360.99%
logo
Lexaria Bioscience Corp. Common Stock
Report Date
Apr 13, 2026 For Q2 26
Estimate
-$0.09
Actual
-$0.06
Surprise
+38.08%
logo
Quince Therapeutics, Inc. Common Stock
Report Date
Apr 10, 2026 For Q4 25
Estimate
-$1.92
Actual
-$7.10
Surprise
-268.68%
logo
Sunshine Biopharma Inc.
Report Date
Apr 03, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.54
Surprise
-96.08%
FAQ
For Q4 2025, Cytokinetics Inc. reported EPS of -$1.50, missing estimates by -0.97%, and revenue of $17.75M, 151.86% above expectations.
The stock price moved down -10.29%, changed from $70.10 before the earnings release to $62.89 the day after.
The next earning report is scheduled for Apr 30, 2026.
Based on 10 analysts, Cytokinetics Inc. is expected to report EPS of -$1.68 and revenue of $8.79M for Q1 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement